Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 14.71
ATRC's Cash to Debt is ranked higher than
82% of the 312 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.04 vs. ATRC: 14.71 )
ATRC' s 10-Year Cash to Debt Range
Min: 1.42   Max: No Debt
Current: 14.71

Equity to Asset 0.84
ATRC's Equity to Asset is ranked higher than
93% of the 304 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.57 vs. ATRC: 0.84 )
ATRC' s 10-Year Equity to Asset Range
Min: -2.15   Max: 0.97
Current: 0.84

-2.15
0.97
F-Score: 3
Z-Score: 13.35
M-Score: -2.05
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -15.23
ATRC's Operating margin (%) is ranked higher than
57% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.43 vs. ATRC: -15.23 )
ATRC' s 10-Year Operating margin (%) Range
Min: -15700   Max: -5.41
Current: -15.23

-15700
-5.41
Net-margin (%) -15.09
ATRC's Net-margin (%) is ranked higher than
57% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.28 vs. ATRC: -15.09 )
ATRC' s 10-Year Net-margin (%) Range
Min: -17980   Max: -6.43
Current: -15.09

-17980
-6.43
ROE (%) -13.32
ATRC's ROE (%) is ranked higher than
57% of the 298 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.60 vs. ATRC: -13.32 )
ATRC' s 10-Year ROE (%) Range
Min: -160.02   Max: -15.8
Current: -13.32

-160.02
-15.8
ROA (%) -10.92
ATRC's ROA (%) is ranked higher than
58% of the 313 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.93 vs. ATRC: -10.92 )
ATRC' s 10-Year ROA (%) Range
Min: -91.98   Max: -11.04
Current: -10.92

-91.98
-11.04
ROC (Joel Greenblatt) (%) -91.25
ATRC's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.59 vs. ATRC: -91.25 )
ATRC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -294.69   Max: -33.57
Current: -91.25

-294.69
-33.57
Revenue Growth (3Y)(%) -0.30
ATRC's Revenue Growth (3Y)(%) is ranked higher than
64% of the 263 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. ATRC: -0.30 )
ATRC' s 10-Year Revenue Growth (3Y)(%) Range
Min: -29.9   Max: 915.8
Current: -0.3

-29.9
915.8
EBITDA Growth (3Y)(%) 35.20
ATRC's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 235 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. ATRC: 35.20 )
ATRC' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -62.7   Max: 120.7
Current: 35.2

-62.7
120.7
EPS Growth (3Y)(%) 20.30
ATRC's EPS Growth (3Y)(%) is ranked higher than
86% of the 229 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. ATRC: 20.30 )
ATRC' s 10-Year EPS Growth (3Y)(%) Range
Min: -45.4   Max: 36.3
Current: 20.3

-45.4
36.3
» ATRC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ATRC Guru Trades in Q1 2014

Steven Cohen 473,478 sh (New)
RS Investment Management 610,500 sh (New)
Jim Simons 38,950 sh (+22.87%)
» More
Q2 2014

ATRC Guru Trades in Q2 2014

RS Investment Management 843,638 sh (+38.19%)
Steven Cohen 300,000 sh (unchged)
Jim Simons Sold Out
» More
Q3 2014

ATRC Guru Trades in Q3 2014

RS Investment Management 862,738 sh (+2.26%)
Steven Cohen Sold Out
» More
Q4 2014

ATRC Guru Trades in Q4 2014

RS Investment Management 1,054,238 sh (+22.20%)
» More
» Details

Insider Trades

Latest Guru Trades with ATRC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.44
ATRC's P/B is ranked higher than
58% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.08 vs. ATRC: 4.44 )
ATRC' s 10-Year P/B Range
Min: 0.64   Max: 14.1
Current: 4.44

0.64
14.1
P/S 5.26
ATRC's P/S is ranked lower than
61% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.32 vs. ATRC: 5.26 )
ATRC' s 10-Year P/S Range
Min: 0.27   Max: 5.53
Current: 5.26

0.27
5.53
EV-to-EBIT -32.46
ATRC's EV-to-EBIT is ranked higher than
52% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 36.87 vs. ATRC: -32.46 )
ATRC' s 10-Year EV-to-EBIT Range
Min: -82   Max: -0.4
Current: -32.46

-82
-0.4
Current Ratio 3.65
ATRC's Current Ratio is ranked higher than
84% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.62 vs. ATRC: 3.65 )
ATRC' s 10-Year Current Ratio Range
Min: 1.96   Max: 7.25
Current: 3.65

1.96
7.25
Quick Ratio 3.09
ATRC's Quick Ratio is ranked higher than
85% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.77 vs. ATRC: 3.09 )
ATRC' s 10-Year Quick Ratio Range
Min: 1.58   Max: 6.88
Current: 3.09

1.58
6.88
Days Inventory 144.56
ATRC's Days Inventory is ranked higher than
69% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 133.28 vs. ATRC: 144.56 )
ATRC' s 10-Year Days Inventory Range
Min: 38.13   Max: 160.74
Current: 144.56

38.13
160.74
Days Sales Outstanding 59.64
ATRC's Days Sales Outstanding is ranked higher than
79% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 69.74 vs. ATRC: 59.64 )
ATRC' s 10-Year Days Sales Outstanding Range
Min: 43.02   Max: 67.09
Current: 59.64

43.02
67.09

Valuation & Return

vs
industry
vs
history
Price/Net Cash 17.56
ATRC's Price/Net Cash is ranked higher than
88% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. ATRC: 17.56 )
ATRC' s 10-Year Price/Net Cash Range
Min: 4.78   Max: 18.21
Current: 17.56

4.78
18.21
Price/Net Current Asset Value 8.75
ATRC's Price/Net Current Asset Value is ranked higher than
86% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. ATRC: 8.75 )
ATRC' s 10-Year Price/Net Current Asset Value Range
Min: 2.67   Max: 32.77
Current: 8.75

2.67
32.77
Price/Tangible Book 6.67
ATRC's Price/Tangible Book is ranked higher than
66% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.30 vs. ATRC: 6.67 )
ATRC' s 10-Year Price/Tangible Book Range
Min: 0.85   Max: 16.1
Current: 6.67

0.85
16.1
Price/DCF (Projected) 21.86
ATRC's Price/DCF (Projected) is ranked higher than
68% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.80 vs. ATRC: 21.86 )
ATRC' s 10-Year Price/DCF (Projected) Range
Min: 20.37   Max: 24.91
Current: 21.86

20.37
24.91
Price/Median PS Value 2.17
ATRC's Price/Median PS Value is ranked higher than
52% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. ATRC: 2.17 )
ATRC' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 2.02
Current: 2.17

0.23
2.02
Earnings Yield (Greenblatt) -3.10
ATRC's Earnings Yield (Greenblatt) is ranked higher than
55% of the 304 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.20 vs. ATRC: -3.10 )
ATRC' s 10-Year Earnings Yield (Greenblatt) Range
Min: -3.9   Max: 0
Current: -3.1

-3.9
0

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:A5I.Germany,
AtriCure Inc was incorporated in the State of Delaware as AtriCure, Inc. on October 31, 2000. It is a medical device company and engaged in developing, manufacturing and selling cardiac surgical ablation systems designed to create precise lesions, in cardiac, or heart, tissue for the treatment of atrial fibrillation, and systems for the exclusion of the left atrial appendage. It has two primary product lines for the ablation of cardiac tissue. Its primary product line for the ablation of cardiac tissue is the AtriCure Synergy Ablation System ('Synergy System'), a bipolar ablation clamp system and related radiofrequency ('RF') ablation devices. It also offers a cryoablation product line, which features reusable and disposable cryoablation devices. Additionally, the Company offers the AtriClip Gillinov-Cosgrove Left Atrial Appendage System ('AtriClip System'), which is designed to safely and effectively exclude the left atrial appendage. Its products are utilized by cardiothoracic surgeons during concomitant open-heart surgical procedures and also during sole-therapy minimally invasive cardiac ablation procedures. During a concomitant open procedure, the surgeon ablates cardiac tissue and/or excludes the left atrial appendage, secondary, or concomitant, to a primary cardiac procedure such as a valve or coronary bypass. Additionally, cardiothoracic surgeons have adopted its products as a treatment alternative for AF patients who may be candidates for sole-therapy minimally invasive surgical procedures. Its Synergy System, which includes its Isolator Synergy clamps, a radiofrequency generator and related switchbox, is cleared by the FDA, for the treatment of patients with persistent and long-standing persistent AF during open-heart concomitant coronary artery bypass grafting and/or valve replacement or repair procedures. In the United States it primarily sells its products to medical centers through its direct sales force. AtriCure Europe, B.V., its wholly-owned subsidiary incorporated and based in the Netherlands, markets and sells its products throughout Europe, the Middle East and Africa, or EMEA, primarily through distributors, while in certain markets, such as Germany and the Benelux region, it sell directly to medical centers. Additionally, it sells its products to other international distributors, mainly in Asia, South America and Canada. The Company's competitors include Biosense Webster, Inc. (a subsidiary of Johnson & Johnson), St. Jude Medical, Inc., and Medtronic, Inc. Its products are medical devices and are subject to regulation by the FDA, as well as other federal and state regulatory bodies in the United States and comparable authorities in other countries.
» More Articles for ATRC

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Amyris, AtriCure, 3D Systems Corporation and Cooper Tire & Rubber Compan Sep 10 2012 
AtriCure Inc. (ATRC) President and CEO and Director David J Drachman sells 40,671 Shares Feb 25 2011 
AtriCure Inc. Reports Operating Results (10-Q) Aug 10 2010 
AtriCure Inc. Reports Operating Results (10-Q) Nov 09 2009 
AtriCure Inc. Reports Operating Results (10-Q) Aug 10 2009 
AtriCure Reports Second Quarter 2009 Financial Results Aug 04 2009 
AtriCure Inc. Reports Operating Results (10-Q) May 07 2009 
AtriCure Announces Web Cast and Conference Call of Fourth Quarter and Full Year 2008 Financial Resul Feb 09 2009 

More From Our Partners
Zacks Rank #5 Additions for Thursday - Tale of the Tape Apr 9 2015 - ZACKS

More From Other Websites
Zacks Rank #5 Additions for Thursday - Tale of the Tape Apr 23 2015
AtriClip System Surpasses 50,000 Units Sold Worldwide Apr 21 2015
AtriClip System Surpasses 50,000 Units Sold Worldwide Apr 21 2015
AtriCure to Announce First Quarter 2015 Financial Results Apr 09 2015
AtriCure to Announce First Quarter 2015 Financial Results Apr 08 2015
AATS Graham Foundation and AtriCure Announce James L. Cox Fellowship in Atrial Fibrillation Surgery Apr 07 2015
AATS Graham Foundation and AtriCure Announce James L. Cox Fellowship in Atrial Fibrillation Surgery Apr 07 2015
ATRICURE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Apr 02 2015
AtriCure (ATRC) is Overbought: Is A Drop Coming? - Tale of the Tape Mar 26 2015
AtriCure to Present at the Needham Healthcare Conference Mar 25 2015
AtriCure to Present at the Needham Healthcare Conference Mar 25 2015
AtriCure, Inc. (Nasdaq: ATRC) to Ring The Nasdaq Stock Market Closing Bell Mar 23 2015
AtriCure, Inc. (Nasdaq: ATRC) to Ring The Nasdaq Stock Market Closing Bell Mar 23 2015
Zacks Rank #5 Additions for Monday - Tale of the Tape Mar 23 2015
AtriCure Launches Solution for Treatment of Post-Thoracotomy Pain Mar 18 2015
AtriCure Launches Solution for Treatment of Post-Thoracotomy Pain Mar 18 2015
Zacks Rank #5 Additions for Wednesday - Tale of the Tape Mar 11 2015
Coverage initiated on AtriCure by Needham Mar 09 2015
ATRICURE, INC. Financials Mar 07 2015
AtriCure Announces 2015 Analyst & Investor Meeting Mar 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK